Blood tests for acute myeloid leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether the levels of certain proteins and blood clotting factors in your blood can help doctors understand acute myeloid leukemia better. It may lead to better ways to monitor the disease and its effects on your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with acute myeloid leukemia (AML).
- You do not have chronic myeloid leukemia (CML).
- You do not have acute lymphoblastic leukemia (ALL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study looks at routine blood test results (called CBC) in people who have just been diagnosed with acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if certain blood levels can help doctors understand the disease better and guide treatment.
This study looks at whether a simple blood test can help predict outcomes in patients with newly diagnosed acute leukemia. The test measures the ratio of two proteins in your blood, which might give doctors clues about how the disease will progress.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.